Duley L, Henderson-Smart D J
Resource Centre for Randomised Trials, Institute of Health Sciences, Old Road, Headington, Oxford, UK, OX3 7LF.
Cochrane Database Syst Rev. 2000(2):CD001449. doi: 10.1002/14651858.CD001449.
Very high blood pressure during pregnancy poses a serious threat to women and their fetuses. The use of drugs to lower blood pressure may reduce this risk.
The objective of this review was to compare different antihypertensive drugs used for rapid treatment of severe hypertension during pregnancy.
We searched the Cochrane Pregnancy and Childbirth Group trials register and the Cochrane Controlled Trials Register.
All randomised trials. Quasi random designs were excluded.
Women with severe hypertension during pregnancy. Women postpartum at trial entry were excluded.
Comparisons of one antihypertensive agent with another.
For the women: blood pressure control, eclampsia, serious maternal morbidity (such as kidney failure and liver failure), Caesarean section, and use of health service resources (such as admission to hospital or intensive care unit). For the baby: death, serious neonatal morbidity, infant and child development, and use of health service resources (such as admission to a special care nursery).
Data were extracted independently by two reviewers to assess eligibility and describe the trial characteristics, and by one reviewer for the meta-analyses. Discrepancies were resolved by discussion. There was no blinding of authorship or results. Whenever possible, unpublished data were sought from investigators.
Thirteen of the 14 trials included in this review were small (range 19-627 women). Of the eight comparisons, five included hydralazine. Diazoxide given as 75mg bolus injections appears to be associated with profound hypotension requiring treatment, and ketanserin is less effective than hydralazine at reducing blood pressure. There is no other evidence that any one of the other antihypertensive agents is better than another for women with severe hypertension during pregnancy.
REVIEWER'S CONCLUSIONS: Until better evidence is available, the choice of antihypertensive should depend on the experience and familiarity of an individual clinician with a particular drug, and on what is known about adverse maternal and fetal side-effects. Exceptions are diazoxide and ketanserin, which are probably not good choices.
孕期血压极高对孕妇及其胎儿构成严重威胁。使用药物降低血压可能会降低这种风险。
本综述的目的是比较用于快速治疗孕期重度高血压的不同降压药物。
我们检索了Cochrane妊娠与分娩组试验注册库和Cochrane对照试验注册库。
所有随机试验。排除半随机设计。
孕期重度高血压女性。排除试验开始时处于产后的女性。
一种降压药物与另一种的比较。
对孕妇而言:血压控制、子痫、严重母体并发症(如肾衰竭和肝衰竭)、剖宫产以及卫生服务资源的使用(如住院或入住重症监护病房)。对婴儿而言:死亡、严重新生儿并发症、婴幼儿发育以及卫生服务资源的使用(如入住特殊护理病房)。
由两名综述员独立提取数据以评估纳入资格并描述试验特征,由一名综述员进行荟萃分析。通过讨论解决分歧。作者身份和结果不设盲。只要有可能,就向研究者索取未发表的数据。
本综述纳入的14项试验中有13项规模较小(涉及19 - 627名女性)。在八项比较中,五项涉及肼屈嗪。以75mg推注方式给药的二氮嗪似乎与需要治疗的严重低血压有关,而酮色林在降低血压方面不如肼屈嗪有效。没有其他证据表明对于孕期重度高血压女性,其他任何一种降压药物比另一种更好。
在获得更好的证据之前,降压药物的选择应取决于临床医生对特定药物的经验和熟悉程度,以及对母体和胎儿不良副作用的了解。二氮嗪和酮色林是例外,它们可能不是好的选择。